Literature DB >> 28445660

Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation.

Simon de Denus1, Eileen O'Meara1, Akshay S Desai2, Brian Claggett2, Eldrin F Lewis2, Grégoire Leclair3, Martin Jutras3, Joël Lavoie4, Scott D Solomon2, Bertram Pitt5, Marc A Pfeffer2, Jean L Rouleau4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28445660      PMCID： PMC5590224          DOI： 10.1056/NEJMc1612601

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.

Authors:  Marc A Pfeffer; Brian Claggett; Susan F Assmann; Robin Boineau; Inder S Anand; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; John F Heitner; Eldrin F Lewis; Eileen O'Meara; Jean-Lucien Rouleau; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Sonja M McKinlay; Bertram Pitt
Journal:  Circulation       Date:  2014-11-18       Impact factor: 29.690

2.  Spironolactone for heart failure with preserved ejection fraction.

Authors:  Bertram Pitt; Marc A Pfeffer; Susan F Assmann; Robin Boineau; Inder S Anand; Brian Claggett; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Brian Harty; John F Heitner; Christopher T Kenwood; Eldrin F Lewis; Eileen O'Meara; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Song Yang; Sonja M McKinlay
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

3.  High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis.

Authors:  Maciej Tomaszewski; Christobelle White; Prashanth Patel; Nicholas Masca; Ravi Damani; Joanne Hepworth; Nilesh J Samani; Pankaj Gupta; Webster Madira; Adrian Stanley; Bryan Williams
Journal:  Heart       Date:  2014-04-02       Impact factor: 5.994
  3 in total
  62 in total

Review 1.  Heart failure with preserved ejection fraction.

Authors:  Andrew R Harper; Hitesh C Patel; Alexander R Lyon
Journal:  Clin Med (Lond)       Date:  2018-04-01       Impact factor: 2.659

2.  Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction.

Authors:  Senthil Selvaraj; Brian Claggett; Sanjiv J Shah; Inder Anand; Jean L Rouleau; Eileen O'Meara; Akshay S Desai; Eldrin F Lewis; Bertram Pitt; Nancy K Sweitzer; James C Fang; Marc A Pfeffer; Scott D Solomon
Journal:  Circ Heart Fail       Date:  2018-11       Impact factor: 8.790

Review 3.  Medical Therapy for Heart Failure Caused by Ischemic Heart Disease.

Authors:  Islam Y Elgendy; Dhruv Mahtta; Carl J Pepine
Journal:  Circ Res       Date:  2019-05-24       Impact factor: 17.367

4.  Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists-what will REWIND add?

Authors:  Keith C Ferdinand; Indrajeet Mahata
Journal:  Ann Transl Med       Date:  2017-12

5.  Detecting Anomalies Among Practice Sites Within Multicenter Trials.

Authors:  Seth A Berkowitz; Kara E Rudolph; Sanjay Basu
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2019-03

6.  Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial.

Authors:  Miranda Merrill; Nancy K Sweitzer; JoAnn Lindenfeld; David P Kao
Journal:  JACC Heart Fail       Date:  2019-03       Impact factor: 12.035

7.  Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction.

Authors:  Patrick Rossignol; Brian Lee Claggett; Jiankang Liu; Orly Vardeny; Bertram Pitt; Faiez Zannad; Scott Solomon
Journal:  Am J Hypertens       Date:  2018-03-10       Impact factor: 2.689

Review 8.  Current Management and Future Directions of Heart Failure With Preserved Ejection Fraction: a Contemporary Review.

Authors:  Chayakrit Krittanawong; Marrick L Kukin
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-20

9.  A Survey of Challenges and Opportunities in Sensing and Analytics for Risk Factors of Cardiovascular Disorders.

Authors:  Nathan C Hurley; Erica S Spatz; Harlan M Krumholz; Roozbeh Jafari; Bobak J Mortazavi
Journal:  ACM Trans Comput Healthc       Date:  2020-12-30

10.  Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points.

Authors:  Stephen J Greene; Adrian F Hernandez; Jie-Lena Sun; Javed Butler; Paul W Armstrong; Justin A Ezekowitz; Faiez Zannad; João Pedro Ferreira; Adrian Coles; Marco Metra; Adriaan A Voors; Robert M Califf; Christopher M O'Connor; Robert J Mentz
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.